139 related articles for article (PubMed ID: 16304177)
1. Population pharmacokinetics of amphotericin B lipid complex in neonates.
Würthwein G; Groll AH; Hempel G; Adler-Shohet FC; Lieberman JM; Walsh TJ
Antimicrob Agents Chemother; 2005 Dec; 49(12):5092-8. PubMed ID: 16304177
[TBL] [Abstract][Full Text] [Related]
2. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats.
Bhamra R; Sa'ad A; Bolcsak LE; Janoff AS; Swenson CE
Antimicrob Agents Chemother; 1997 May; 41(5):886-92. PubMed ID: 9145839
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis.
Walsh TJ; Whitcomb P; Piscitelli S; Figg WD; Hill S; Chanock SJ; Jarosinski P; Gupta R; Pizzo PA
Antimicrob Agents Chemother; 1997 Sep; 41(9):1944-8. PubMed ID: 9303390
[TBL] [Abstract][Full Text] [Related]
4. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations.
Groll AH; Lyman CA; Petraitis V; Petraitiene R; Armstrong D; Mickiene D; Alfaro RM; Schaufele RL; Sein T; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3418-23. PubMed ID: 17005824
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies.
Adedoyin A; Bernardo JF; Swenson CE; Bolsack LE; Horwith G; DeWit S; Kelly E; Klasterksy J; Sculier JP; DeValeriola D; Anaissie E; Lopez-Berestein G; Llanos-Cuentas A; Boyle A; Branch RA
Antimicrob Agents Chemother; 1997 Oct; 41(10):2201-8. PubMed ID: 9333048
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases.
Hong Y; Shaw PJ; Nath CE; Yadav SP; Stephen KR; Earl JW; McLachlan AJ
Antimicrob Agents Chemother; 2006 Mar; 50(3):935-42. PubMed ID: 16495254
[TBL] [Abstract][Full Text] [Related]
7. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model.
Goldblum D; Rohrer K; Frueh BE; Theurillat R; Thormann W; Zimmerli S
Ophthalmic Res; 2004; 36(3):172-6. PubMed ID: 15103209
[TBL] [Abstract][Full Text] [Related]
8. Penetration of amphotericin B lipid formulations into pleural effusion.
Weiler S; Bellmann-Weiler R; Joannidis M; Bellmann R
Antimicrob Agents Chemother; 2007 Nov; 51(11):4211-3. PubMed ID: 17785511
[TBL] [Abstract][Full Text] [Related]
9. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities.
Ramaswamy M; Peteherych KD; Kennedy AL; Wasan KM
Antimicrob Agents Chemother; 2001 Apr; 45(4):1184-91. PubMed ID: 11257033
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal penetration of amphotericin B lipid complex and fluconazole in a pediatric patient with fungal peritonitis.
Blowey DL; Garg UC; Kearns GL; Warady BA
Adv Perit Dial; 1998; 14():247-50. PubMed ID: 10649734
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis.
Capilla J; Clemons KV; Sobel RA; Stevens DA
J Antimicrob Chemother; 2007 Sep; 60(3):673-6. PubMed ID: 17646202
[TBL] [Abstract][Full Text] [Related]
12. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies.
Wasan KM; Kennedy AL; Cassidy SM; Ramaswamy M; Holtorf L; Chou JW; Pritchard PH
Antimicrob Agents Chemother; 1998 Dec; 42(12):3146-52. PubMed ID: 9835506
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of cisapride in neonates.
Odoul F; Le Guellec C; Henrot A; Saliba E; Levron JC; Saux MC; Paintaud G; Autret-Leca E
Eur J Clin Pharmacol; 2002 Nov; 58(8):507-13. PubMed ID: 12451427
[TBL] [Abstract][Full Text] [Related]
15. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
Zhang Z; Diener RM; Lipman JM
Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
[TBL] [Abstract][Full Text] [Related]
16. Impact of ontogeny on linezolid disposition in neonates and infants.
Kearns GL; Jungbluth GL; Abdel-Rahman SM; Hopkins NK; Welshman IR; Grzebyk RP; Bruss JB; Van Den Anker JN;
Clin Pharmacol Ther; 2003 Nov; 74(5):413-22. PubMed ID: 14586382
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Candida infections with amphotericin B lipid complex.
Ito JI; Hooshmand-Rad R
Clin Infect Dis; 2005 May; 40 Suppl 6():S384-91. PubMed ID: 15809924
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
19. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
Zhou H; Mayer PR; Wajdula J; Fatenejad S
J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
[TBL] [Abstract][Full Text] [Related]
20. The experience is CLEAR.
Chandrasekar P
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():31-5. PubMed ID: 16707248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
